Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Empirical Antimicrobial Therapy and QTc Interval Prolongation in Emergency Medicine

Author(s): Marianna Suppa and Luca Marino*

Volume 17, Issue 1, 2022

Published on: 29 June, 2021

Page: [13 - 16] Pages: 4

DOI: 10.2174/1574886316666210629150105

Price: $65

Abstract

Background: QTc prolongation is common in dangerous clinical conditions, associated with an increased risk of life-threatening arrhythmia torsades de pointes. The goal of this short communication is to evaluate the principal causes of risk of QTc prolongation that are observed in an emergency department and discuss the differences between drug- and non-drug-associated factors.

Methods: The retrospective analysis was carried out on 130 patients that presented a QTc prolongation (>480 ms for man and >470 for female, respectively), admitted to the emergency department of a single Italian hospital. Patients with pace-maker (22) were excluded from this study. For each patient, a minimum of 3 ECGs (12 leads) were recorded. Attention was paid on electrolytes disturbances and to the pharmacotherapy, with a particular emphasis to the use of antibiotics.

Results: Mean age of the patients was 79.6 years (SD=11.3) and females and males were almost equally present (46.6% F, 53.7% M). The average QTc value was 492.2 ms (493.3 ms F, 492.8 M). The patients were divided in those with electrolytes disturbances (24.0%), antimicrobial therapy (35.2%), both antimicrobial therapy and electrolytes disturbances (24.1%), and other causes of QTc prolongation (16.7%).

Conclusion: This analysis shows the relevance of the empirical therapy established at the admission, in particular for infective diseases, as an important risk factor for the prolongation of QTc. Other factors that can increase the risk are electrolytes alterations, advanced age, cardiovascular diseases, and drug-drug interaction.

Keywords: QTc prolongation, risk factors, antibiotic therapy, arrhythmia, drug safety, emergency medicine.

« Previous Next »
Graphical Abstract

[1]
Keller GA, Alvarez PA, Ponte ML, et al. Drug-induced QTc interval prolongation: A multicenter study to detect drugs and clinical factors involved in every day practice. Curr Drug Saf 2016; 11(1): 86-98.
[http://dx.doi.org/10.2174/1574886311207040262] [PMID: 26537523]
[2]
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121(8): 1047-60.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192704] [PMID: 20142454]
[3]
Trinkley KE, Page RL II, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: Essentials for clinicians. Curr Med Res Opin 2013; 29(12): 1719-26.
[http://dx.doi.org/10.1185/03007995.2013.840568] [PMID: 24020938]
[4]
Pourmand A, Mazer-Amirshahi M, Chistov S, Sabha Y, Vukomanovic D, Almulhim M. Emergency department approach to QTc prolongation. Am J Emerg Med 2017; 35(12): 1928-33.
[http://dx.doi.org/10.1016/j.ajem.2017.08.044] [PMID: 28855066]
[5]
Franchi C, Ardoino I, Rossio R, et al. Prevalence and risk factors associated with use of QT-prolonging drugs in hospitalized older people. Drugs Aging 2016; 33(1): 53-61.
[http://dx.doi.org/10.1007/s40266-015-0337-y] [PMID: 26693921]
[6]
Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third national health and nutrition examination survey. Eur J Cardiovasc Prev Rehabil 2005; 12(4): 363-8.
[http://dx.doi.org/10.1097/01.hjr.0000173110.21851.a9] [PMID: 16079644]
[7]
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: Systematic review of the evidence. Int J Clin Pharm 2017; 39(1): 16-25.
[http://dx.doi.org/10.1007/s11096-016-0414-2] [PMID: 28012118]
[8]
CredibleMeds AZCERT. Available from: https://www.crediblemeds.org [Accessed 25 November 2020]
[9]
Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf 2010; 5(1): 85-92.
[http://dx.doi.org/10.2174/157488610789869184] [PMID: 20210724]
[10]
Noss K, Aguero SM, Reinaker T. Assessment of prescribing and monitoring habits for patients taking an antiarrhythmic and concomitant QTc-prolonging antibiotic. Pharmacy (Basel) 2017; 5(4): 61.
[http://dx.doi.org/10.3390/pharmacy5040061] [PMID: 29104235]
[11]
Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: Administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol 2016; 72(7): 859-67.
[http://dx.doi.org/10.1007/s00228-016-2043-z] [PMID: 27023463]
[12]
Lee RA, Guyton A, Kunz D, Cutter GR, Hoesley CJ. Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center. J Hosp Med 2016; 11(1): 15-20.
[http://dx.doi.org/10.1002/jhm.2448] [PMID: 26287278]
[13]
Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. Int J Med Sci 2019; 16(7): 1018-22.
[http://dx.doi.org/10.7150/ijms.34141] [PMID: 31341415]
[14]
Wiśniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol 2016; 17: 12.
[http://dx.doi.org/10.1186/s40360-016-0053-1] [PMID: 26960809]
[15]
Rabkin SW. Aging effects on QT interval: Implications for cardiac safety of antipsychotic drugs. J Geriatr Cardiol 2014; 11(1): 20-5.
[PMID: 24748877]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy